Dhruv Bansal

Dhruv Bansal

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
BPBen Ponvilawan
Ben Ponvilawan
AKAbdul Wali Khan
Abdul Wali Khan
JSJanakiraman Subramanian
Janakiraman Subramanian
DBDhruv Bansal
Dhruv Bansal
Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatment, and 11% develop severe irAEs requiring interventions. A predictive test for irAEs would be a crucial tool for monitoring for complications during and after ICI therapy. We performed an extensive review of potential predictive biomarkers for irAEs in patients who received ICI therapy. Currently, only thyroid-stimulating hormone is utilized in common clinical practice. This is due to the unavailability of commercial tests and unclear predictive values from various studies. Given the lack of single strong predictive biomarkers, some novel approaches using composite scores using genomic, transcriptomics, cytokine levels, or clinical parameters appear appealing. Still, these have yet to be validated and incorporated into clinical practice. Further research conducted to validate the models before implementing them into real-world settings will be of the utmost importance for irAE prediction.

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
Himil MahadeviaHimil Mahadevia
Himil Mahadevia
BPBen Ponvilawan
Ben Ponvilawan
AAAmmar Al-Obaidi
Ammar Al-Obaidi
JBJennifer Buckley
Jennifer Buckley
JSJanakiraman Subramanian
Janakiraman Subramanian
DBDhruv Bansal
Dhruv Bansal
Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in various tumors. A significant therapeutic challenge with either ICIs or PARP inhibitors as monotherapy is treatment failure from intrinsic primary resistance or the development of secondarily acquired resistance after a period of responsiveness. The combination of PARP inhibitors and ICIs could mitigate this by potentiating treatment response. We describe an 83-year-old male patient who initially presented with abdominal pain, and weight loss along with alternating constipation and diarrhea. Imaging and biopsy revealed metastatic esophageal adenocarcinoma. Genomic testing revealed germline BRCA2 mutation. The patient initially underwent a few cycles of chemoimmunotherapy. However, due to intolerance to chemotherapy, the patient’s case was discussed at a multidisciplinary molecular tumor board. He was switched to PARP inhibitor olaparib and ICI nivolumab. This combination led to a durable complete response. A combination of poly-ADP ribose polymerase inhibitor (PARPi) plus ICI may work in synergy through various mechanisms including enhanced neoantigen expression, release of immune-activating cytokines, and increased programmed death-ligand 1 expression. This may culminate in accentuated efficacy outcomes with a manageable safety profile. This exceptional response with ICI and PARPi in our case is consistent with the synergistic value of this combination, and prospective studies are warranted to definitively characterize clinical utility.

18 August 2023 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
BPBen Ponvilawan
Ben Ponvilawan
PSParth Sharma
Parth Sharma
Himil MahadeviaHimil Mahadevia
Himil Mahadevia
JSJanakiraman Subramanian
Janakiraman Subramanian
DBDhruv Bansal
Dhruv Bansal

1 September 2023 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
Himil MahadeviaHimil Mahadevia
Himil Mahadevia
LKLara Kujtan
Lara Kujtan
MRMarc Roth
Marc Roth
PSParth Sharma
Parth Sharma
JBJennifer R. Buckley
Jennifer R. Buckley
DBDhruv Bansal
Dhruv Bansal
We present 2 cases of cancer of unknown origin in which RNA-based cancer classification testing provided vital insight and directed treatment management. The tissue of origin could not be determined in both of these patients utilizing morphology and immunohistochemical analysis of the tissue samples. Next-generation sequencing and tumor-of-origin testing using an RNA-based molecular cancer classifier were performed to elucidate the possible tissue of origin. A 61-year-old male with a history of localized basal cell carcinoma presented with a 4.4-cm axillary lymph node in addition to upper extremity edema and supraclavicular lymphadenopathy. RNA-based tumor origin testing revealed skin basal or squamous cell carcinoma as the likely tissue of origin, with a probability of 97%. He received vismodegib, a hedgehog inhibitor, after progression on cemiplimab and experienced a partial response by RECIST criteria, which is currently ongoing for over a year. A 74-year-old female patient with a remote history of ovarian cancer for which she underwent resection and adjuvant chemotherapy presented 15 years later with abdominal pain. The diagnostic workup revealed a 2-cm pancreatic mass and enlarged peritoneal lymph nodes. RNA sequencing revealed a 99% likelihood of the tissue of origin being serous ovarian carcinoma. Subsequently, she underwent surgery and adjuvant chemotherapy and is currently in remission with letrozole maintenance. Genomic data already plays a crucial role in therapeutic decision-making for individuals with cancer. These cases highlight the complementary role of genomic data in the diagnostic workup of cancer, leading to favorable patient outcomes.


1 May 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
DBDhruv Bansal
Dhruv Bansal
BPBen Ponvilawan
Ben Ponvilawan
DGDmitrii Grachev
Dmitrii Grachev
VKVladimir Kushnarev
Vladimir Kushnarev
ATArtem Tarasov
Artem Tarasov
JSJanakiraman Subramanian
Janakiraman Subramanian
PURPOSE: Current predictive biomarkers for immune checkpoint inhibitor (ICI)–based therapy in patients with lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC), such as PD-L1 protein expression or tumor mutation burden, are still suboptimal. We aim to explore immunophenotypic factors as potential biomarkers in this patient population. METHODS: Clinical, genomic, and transcriptomic data from five patient cohorts, consisting of three publicly available data and two retrospective cohorts, were included. Immune tumor microenvironment (TME) subtype and tertiary lymphoid structure (TLS) signature were evaluated using RNA expression data, and deconvolutional cellular decomposition of tumor samples was performed using the Kassandra algorithm. Survival analysis was performed using a log-rank test and multivariate Cox regression. All statistical analyses were performed using Python version 3.10. RESULTS: In total, 514 patients were included in this analysis. A minority of LUAD (40.8%) had an immune-hot phenotype, which corresponded to better overall survival (OS) and progression-free survival (PFS) than the immune-cold phenotype. TLS-high signature was also associated with a superior ICI response rate and improved PFS, even with multivariate adjustments. Increased T-cell and macrophage infiltration and trafficking were predictive of ICI response. PD-L1 status and KEAP1 or STK11 mutations did not affect the response rates but were associated with poorer OS and PFS. CONCLUSION: Dynamic and active immune recruitment, indicated by immune-hot TME and high TLS score, was predictive of ICI benefit in patients with LUAD. Further prospective studies are warranted to expand to other treatment combinations with PD-(L)1 inhibitors.